Keyword :   pembrolizumab

KEYTRUDA (pembrolizumab): expanding opportunities in the treatment of resectable non-small cell lung cancer
Т. 15, №2 (58)
Pembrolizumab+chemotherapy versus atezolizumab+chemotherapy+/−bevacizumab for the first-line treatment of non-squamous NSCLC: a matching-adjusted indirect comparison
Т. 15, №1 (57)
Pembrolizumab plus chemotherapy for metastatic NSCLC with programmed cell death ligand 1 tumor proportion score <1%: pooled analysis of outcomes after five years of follow-up
Т. 15, №1 (57)
Pembrolizumab vs Placebo as Adjuvant Therapy for High-Risk Stage II Melanoma: Long-Term Follow-Up, Rechallenge, and Crossover in KEYNOTE-716
Т. 14, №4 (56)
Seven-year analysis of adjuvant pembrolizumab versus placebo in stage III melanoma in the EORTC1325 / KEYNOTE-054 trial
Т. 14, №4 (56)
KEYNOTE-006 study: results of 10-year follow-up of pembrolizumab versus ipilimumab in advanced melanoma
Т. 14, №4 (56)
Expanding the role of immuno-oncology treatment in the management of patients with melanoma or triple-negative breast cancer
Т. 13, №4 (52)
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesothelioma
Author:Nemish I.L. Т. 13, № 3 (51)
Pembrolizumab is first-line treatment for patients with advanced non-small cell lung cancer in both mono and combination regimens
T. 10, № 1-2 (37-38)
Immunotherapy of Hodgkin’s lymphoma: a new treatment strategy
Author:Kryachok I. Т. 8, № 2 (30) 2018
A clinical case of treating of a patient with melanoma using checkpoint inhibitor pembolizumab (anti-PD-1 monoclonal antibody)
Author:Kosinova V.G. №4(28) 2017